Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells

Chemico-Biological Interactions

Volumn 123, Issue 1, 1999, Pages 11-29

  O'Neill, Ciaran F ^a   Hunakova, Luba ^b   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

DNA repair; Platinum; Resistance; Trans

Indexed keywords

CIS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; CISPLATIN; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM COMPLEX; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL LINE; DNA REPAIR; DRUG POTENCY; FLUORESCENCE MICROSCOPY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; ISOMERISM; OVARY CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL DIVISION; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PLATINUM; STEREOISOMERISM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032743555     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00115-5     Document Type: Article

References (38)

1. Gore M.E., Fryatt E., Wiltshaw E., Dawson T., Robinson B.A., Calvert A.H. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer. 60:1989;767-769.
2. Kelland L.R. Platinum complexes. Teicher B.A. Cancer Therapeutics, Experimental and Clinical Agents. 1997;93-112 Humana, Totowa, NJ.
3. Kelland L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A., Harrap K.R. Preclinical antitumor evaluation of bis-acetato-amminedichloro cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 53:1993;2581-2586.
4. McKeage M.J., Raynaud F., Ward J., Berry C., Odell D., Kelland L.R., Murrer B., Santabarbara P., Harrap K.R., Judson I.R. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J. Clin. Oncol. 15:1997;2691-2700.
5. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J.-J., Brienza S., Itzhaki M., Metzger G., N'Daw D., Vignoud J., Abad A., Francois E., Gamelin E., Marty M., Sastre J., Seitz J.-F., Ychou M. Two consecutive phase II trials of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
6. Raynaud F.I., Boxall F.E., Goddard P.M., Valenti M., Jones M., Murrer B.A., Abrams M., Kelland L.R. Cis-amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin. Cancer Res. 3:1997;2063-2074.
7. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloro platinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46:1986;1972-1979.
8. Farrell N., Ha T.T.B., Souchard J.-P., Wimmer F.L., Cros S., Johnson N.P. Cytostatic trans-platinum(II) complexes. J. Med. Chem. 32:1989;2240-2241.
9. Van Beusichem M., Farrell N. Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole) platinum(II). Inorg. Chem. 31:1992;634-639.
10. Farrell N., Kelland L.R., Roberts J.D., van Beusichem M. Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res. 52:1992;5065-5072.
11. Connors T.A., Cleare M.J., Harrap K.R. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep. 63:1979;1499-1502.
12. Coluccia M., Nassi A., Loseto F., Boccarelli A., Mariggio M.A., Giordano D., Intini F.P., Caputo P., Natile G. A trans-platinum complex showing higher antitumor activity than the cis congeners. J. Med. Chem. 36:1993;510-512.
13. Coluccia M., Boccarelli A., Mariggio M.A., Cardellicchio N., Caputo P., Intini F.P., Natile G. Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem.-Biol. Interact. 98:1995;251-266.
14. 2]. Nucl. Acids Res. 24:1996;336-341.
15. 2]. Mol. Pharmacol. 52:1997;354-361.
16. Kelland L.R., Barnard C.F.J., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer B.A., Harrap K.R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 54:1994;5618-5622.
17. Kelland L.R., Barnard C.F.J., Evans I.G., Murrer B.A., Theobald B.R.C., Wyer S.B., Goddard P.M., Jones M., Valenti M., Bryant A., Rogers P.M., Harrap K.R. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem. 38:1995;3016-3024.
18. Mellish K.J., Barnard C.F.J., Murrer B.A., Kelland L.R. DNAbinding properties of novel cis and trans platinum-based anticancer agents in two human ovarian carcinoma cell lines. Int. J. Cancer. 62:1995;711-723.
19. Goddard P.M., Orr R.M., Valenti M.R., Barnard C.F.J., Murrer B.A., Kelland L.R., Harrap K.R. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. Anticancer Res. 16:1996;33-38.
20. O''Neill C.F., Ormerod M.G., Robertson D., Titley J.C., Cumber-Walseer Y., Kelland L.R. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex. Br. J. Cancer. 74:1996;1037-1045.
21. Raynaud F.I., Mistry P., Donaghue A., Poon G.K., Kelland L.R., Barnard C.F.J., Murrer B.A., Harrap K.R. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother. Pharmacol. 38:1996;155-162.
22. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R. Biological properties often human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer. 59:1989;527-534.
23. Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A., Harrap K.R. Mechanism-related circumvention of acquired cisdiamminedichloro platinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res. 52:1992;3857-3864.
24. O'Neill C.F., Orr R.M., Kelland L.R., Harrap K.R. Comparison of platinum (Pt) binding to DNA and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell. Pharmacol. 2:1995;1-7.
25. Ormerod M., O'Neill C., Robertson D., Kelland L.R., Harrap K.R. Cis-diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 37:1996;463-471.
26. Grimaldi K.A., Bingham J.P., Souhami R.L., Hartley J.A. DNA damage by anticancer agents: mapping in cells at the subgene level with quantitative PCR. Anal. Biochem. 222:1994;236-242.
27. Koberle B., Payne J., Grimaldi K.A., Hartley J.A., Masters J.R.W. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem. Pharmacol. 52:1996;1729-1734.
28. Pestell K.E., Medlow C.J., Titley JC, Kelland L.R., Walton M.I. Characterisation of the p53 status, bcl-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int. J. Cancer. 77:1998;913-918.
29. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52:1992;4196-4199.
30. Mistry P., Kelland L.R., Abel G., Sidhur S., Harrap K.R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br. J. Cancer. 64:1991;215-220.
31. Jones J.C., Zhen W., Reed E., Parker R.J., Sancar A., Bohr V.A. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J. Biol. Chem. 266:1991;7101-7107.
32. Zhen W., Link C.J., O'Connor P.M., Reed E., Parker R., Howell S.B., Bohr V.A. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin resistant human ovarian cancer cell lines. Mol. Cell Biol. 12:1992;3689-3698.
33. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F., Hamilton T.C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 47:1994;689-697.
34. Petersen L.N., Mamenta E.L., Stevenser T., Chaney S.G., Bohr V.A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines and studies on carrier ligand specificity. Carcinogenesis. 17:1996;2597-2602.
35. Mellish K.J., Kelland L.R. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichlorocyclohexylamine platinum(IV) (JM216) in two human ovarian carcinoma cell lines. Cancer Res. 54:1994;6194-6200.
36. 2] on B-Z transition in DNA. Anticancer Drug Des. 12:1997;295-309.
37. 3, pyridine. Biochemistry. 32:1993;9632-9638.
38. 3)(quinoline)]. Eur. J. Biochem. 254:1998;547-557.